Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.60 |
| ▸ | NPC1 | O15118 | 2/20 | 0.60 |
| ▸ | RAB9A | P51151 | 2/20 | 0.60 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.57 |
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.51 |
| ▸ | GRIN2B | Q13224 | 9/20 | 0.49 |
| ▸ | HTT | P42858 | 1/20 | 0.49 |
| ▸ | CYP2D6 | P10635 | 4/20 | 0.48 |
| ▸ | CYP2C9 | P11712 | 4/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.46 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.45 |
| ▸ | BCHE | P06276 | 1/20 | 0.44 |
| ▸ | F13A1 | P00488 | 1/20 | 0.44 |
| ▸ | TGM2 | P21980 | 1/20 | 0.44 |
| ▸ | TGM1 | P22735 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21458882 | 1.00 | SMN1; SMN2 (0.60) | SMN1; SMN2NPC1RAB9ACYP2C19MEN1 | |
| SCHEMBL17765068 | 0.93 | SMN1; SMN2 (0.54) | SMN1; SMN2NPC1RAB9ACYP2C19MEN1 | |
| SCHEMBL16333465 | 0.93 | SMN1; SMN2 (0.54) | SMN1; SMN2NPC1RAB9ACYP2C19MEN1 | |
| SCHEMBL30380317 | 0.93 | SMN1; SMN2 (0.62) | SMN1; SMN2NPC1RAB9ACYP2C19MEN1 | |
| SCHEMBL1320183 | 0.93 | SMN1; SMN2 (0.65) | SMN1; SMN2NPC1RAB9ACYP2C19MEN1 | |
| SCHEMBL28978024 | 0.88 | SMN1; SMN2 (0.62) | SMN1; SMN2NPC1RAB9ACYP2C19MEN1 | |
| SCHEMBL16340503 | 0.86 | SMN1; SMN2 (0.56) | SMN1; SMN2NPC1RAB9ACYP2C19MEN1 | |
| SCHEMBL16333453 | 0.86 | SMN1; SMN2 (0.56) | SMN1; SMN2NPC1RAB9ACYP2C19MEN1 | |
| SCHEMBL4112297 | 0.85 | SMN1; SMN2 (0.62) | SMN1; SMN2NPC1RAB9ACYP2C19MEN1 | |
| SCHEMBL21906825 | 0.85 | SMN1; SMN2 (0.59) | SMN1; SMN2NPC1RAB9ACYP2C19MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12552783-B2 | Modulators of proteolysis and associated methods of use | ARVINAS OPERATIONS, INC. (US) | 2026-02-17 | — | — | US | disclosed |
| CN-117510504-A | Protein kinase degradation agent, medicine and application | 深圳市新樾生物科技有限公司 | 2024-02-06 | — | — | CN | disclosed |
| US-20220402907-A1 | MODULATORS OF PROTEOLYSIS AND ASSOCIATED METHODS OF USE | YALE UNIVERSITY | 2022-12-22 | — | — | US | disclosed |
| US-11161841-B2 | Modulators of proteolysis and associated methods of use | ARVINAS OPERATIONS, INC. (US) | 2021-11-02 | — | — | US | disclosed |
| EP-3774777-A2 | MODULATORS OF PROTEOLYSIS AND ASSOCIATED METHODS OF USE | Arvinas Operations, Inc. (US) | 2021-02-17 | — | — | EP | disclosed |
| CN-112218859-A | Modulators of proteolysis and related methods of use | 阿尔维纳斯运营股份有限公司 | 2021-01-12 | — | — | CN | disclosed |
| US-20190315732-A1 | MODULATORS OF PROTEOLYSIS AND ASSOCIATED METHODS OF USE | ARVINAS OPERATIONS, INC. | 2019-10-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190315732-A1 | MODULATORS OF PROTEOLYSIS AND ASSOCIATED METHODS OF USE | MDM2, CRBN, VHL | SMN1; SMN2 697/4885NPC1 3779/4885RAB9A 3392/4885 |
| US-20220402907-A1 | MODULATORS OF PROTEOLYSIS AND ASSOCIATED METHODS OF USE | MDM2, CRBN, VHL | SMN1; SMN2 697/4885NPC1 3779/4885RAB9A 3392/4885 |
| US-12552783-B2 | Modulators of proteolysis and associated methods of use | CRBN, ADRM1, MDM2 | SMN1; SMN2 903/4885NPC1 3337/4885RAB9A 2309/4885 |
| US-11161841-B2 | Modulators of proteolysis and associated methods of use | MDM2, CRBN, VHL | SMN1; SMN2 697/4885NPC1 3779/4885RAB9A 3392/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.